专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130030000A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS 审中-公开
标题翻译：用于治疗疼痛和其他症状的药物组合物
公开(公告)号：US20130030000A1
公开(公告)日：2013-01-31
申请号：US13574303
申请日：2011-01-25
申请人： Harry R. Chobanian , Linus S. Lin , Ping Liu , Marc D. Chioda , Robert J. DeVita , Ravi P. Nargund , Yan Guo , Terence G. Hamill , Wenping Li , Darrell Arthur Henze
发明人： Harry R. Chobanian , Linus S. Lin , Ping Liu , Marc D. Chioda , Robert J. DeVita , Ravi P. Nargund , Yan Guo , Terence G. Hamill , Wenping Li , Darrell Arthur Henze
IPC分类号： A61K31/497 , A61K31/506 , A61K31/513 , A61K31/4439 , A61K31/421 , A61K31/4245 , A61K31/4545 , A61K31/501 , A61K31/4725 , A61K31/4709 , A61P29/00 , A61P25/22 , A61P3/04 , A61P27/02 , A61P11/06 , A61P27/06 , A61P9/00 , A61P25/24 , A61P43/00 , A61P19/02 , A61P25/28 , A61P25/18 , A61P25/30 , A61P25/16 , A61P25/08 , A61P11/00 , A61P35/00 , A61P1/00 , A61P1/04 , A61P1/12 , A61P17/04 , A61P1/16 , A61P25/06 , A61P25/02 , A61K31/444
CPC分类号： A61K31/422 , A61K31/4178
摘要： The present invention is directed to a composition useful for the treatment of a FAAH mediated disease, disorder or conditions comprising a FAAH inhibitor and a second activation, comprising a selected imidazole or oxazole FAAH inhibitor and a second active agent. The compositions will be useful in the treatment of a wide range of disease, disorder, or conditions including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease. In another aspect the invention discloses herein is directed to compositions useful in the treatment of neuropathic and nociceptive pain, said compositions comprising etoricoxib.
摘要翻译：本发明涉及可用于治疗包含选择的咪唑或恶唑FAAH抑制剂和第二活性剂的FAAH介导的疾病，病症或包含FAAH抑制剂和第二活化的病症的组合物。该组合物可用于治疗广泛的疾病，病症或病症，包括骨关节炎，类风湿性关节炎，糖尿病性神经病，带状疱疹后神经痛，肌肉痛和纤维肌痛，以及急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病，和帕金森病。另一方面，本发明公开了本发明涉及用于治疗神经性疼痛和伤害性疼痛的组合物，所述组合物包含埃托考昔。

2. 发明授权

US07576239B2 Substituted amides 失效
标题翻译：取代酰胺
公开(公告)号：US07576239B2
公开(公告)日：2009-08-18
申请号：US12008728
申请日：2008-01-14
申请人： Linus S. Lin , William K. Hagmann , Sanjeev Kumar , Wenji Yin , George Doss
发明人： Linus S. Lin , William K. Hagmann , Sanjeev Kumar , Wenji Yin , George Doss
IPC分类号： C07C233/05 , C07D213/02 , A61K31/44
CPC分类号： C07D213/64 , C07C255/60 , C07C275/24 , C07C2601/04
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
摘要翻译：结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。

3. 发明申请

US20080194645A1 Substituted amides 失效
标题翻译：取代酰胺
公开(公告)号：US20080194645A1
公开(公告)日：2008-08-14
申请号：US12008728
申请日：2008-01-14
申请人： Linus S. Lin , William K. Hagmann , Sanjeev Kumar , Wenji Yin , George Doss
发明人： Linus S. Lin , William K. Hagmann , Sanjeev Kumar , Wenji Yin , George Doss
IPC分类号： A61K31/44 , C07D211/86 , A61P25/06 , A61P25/28
CPC分类号： C07D213/64 , C07C255/60 , C07C275/24 , C07C2601/04
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
摘要翻译：结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。

4. 发明授权

US06559174B2 N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors 失效
公开(公告)号：US06559174B2
公开(公告)日：2003-05-06
申请号：US10097028
申请日：2002-03-13
申请人： Linus S. Lin , Shrenik K. Shah , Linda L. Chang , William K. Hagmann , Richard A. Mumford
发明人： Linus S. Lin , Shrenik K. Shah , Linda L. Chang , William K. Hagmann , Richard A. Mumford
IPC分类号： A61K3147
CPC分类号： C07D401/12 , A61K31/4709 , A61K31/4745 , C07D401/14 , C07D487/04
摘要： Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

5. 发明授权

US08318767B2 Substituted imidazoles as bombesin receptor subtype-3 modulators 失效
公开(公告)号：US08318767B2
公开(公告)日：2012-11-27
申请号：US13327093
申请日：2011-12-15
申请人： David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Jian Liu , Michael M.-C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
发明人： David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Jian Liu , Michael M.-C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
IPC分类号： A61K31/437 , A61K31/4439 , A61K31/427 , A61K31/4155 , C07D417/10 , C07D233/64 , C07D471/04 , C07D401/14 , C07D401/10 , C07D403/10
CPC分类号： C07D401/10 , C07D233/64 , C07D401/14 , C07D403/10 , C07D417/10 , C07D471/04
摘要： Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

6. 发明申请

US20120088788A1 SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS 失效
标题翻译：作为BOMBESIN受体亚型3调节剂的替代咪唑
公开(公告)号：US20120088788A1
公开(公告)日：2012-04-12
申请号：US13327093
申请日：2011-12-15
申请人： David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Jian Liu , Michael M.C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
发明人： David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Jian Liu , Michael M.C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
IPC分类号： A61K31/437 , A61K31/4439 , C07D417/10 , A61K31/427 , A61P3/04 , A61K31/4155 , C07D233/64 , A61K31/4174 , C07D471/04 , C07D401/14 , C07D401/10 , C07D403/10
CPC分类号： C07D401/10 , C07D233/64 , C07D401/14 , C07D403/10 , C07D417/10 , C07D471/04
摘要： Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
摘要翻译：某些新颖的取代的咪唑是人类bombesin受体的配体，特别是人类bombesin受体亚型-3（BRS-3）的选择性配体。因此，它们可用于治疗，控制或预防对调节BRS-3的疾病和病症，例如肥胖症和糖尿病。

7. 发明申请

US20110144119A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH 有权
标题翻译：奥沙唑衍生物作为FAAH的抑制剂有用
公开(公告)号：US20110144119A1
公开(公告)日：2011-06-16
申请号：US13057415
申请日：2009-07-30
申请人： Harry Chobanian , Linus S. Lin , Ping Liu , Marc D. Chioda , Robert J. DeVita , Ravi P. Nargund , Yan Guo
发明人： Harry Chobanian , Linus S. Lin , Ping Liu , Marc D. Chioda , Robert J. DeVita , Ravi P. Nargund , Yan Guo
IPC分类号： A61K31/501 , C07D413/14 , A61K31/497 , C07D413/04 , A61K31/444 , A61K31/4439 , A61K31/506 , C07D263/46 , A61K31/421 , C07D413/10 , A61K31/4245 , C07D413/12 , A61K31/4545 , C07D417/14 , A61K31/4725 , A61K31/4709 , A61P19/02 , A61P29/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/20 , A61P25/28 , A61P25/16
CPC分类号： C07D413/14 , C07D263/46 , C07D271/06 , C07D271/10 , C07D413/04 , C07D413/10 , C07D417/04 , C07D417/14
摘要： The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.
摘要翻译：本发明涉及可用作脂肪酸酰胺水解酶（FAAH）抑制剂的某些恶唑衍生物。本发明还涉及包含这些化合物作为活性成分的药物制剂，以及这些化合物及其制剂在治疗某些疾病，包括骨关节炎，类风湿性关节炎，糖尿病性神经病变，带状疱疹后神经痛，ke肉肌痛和纤维肌痛等方面的用途。作为急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病和帕金森病。

8. 发明申请

US20090258884A1 Substituted amides 有权
公开(公告)号：US20090258884A1
公开(公告)日：2009-10-15
申请号：US12386336
申请日：2009-04-16
申请人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza, JR.
发明人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza, JR.
IPC分类号： A61K31/497 , C07D213/56 , A61K31/4412 , C07C235/00 , A61K31/165 , C07D401/12 , A61K31/444 , A61K31/4439 , A61K31/506 , C07D249/04 , A61K31/4192 , C07D409/12 , A61K31/4436 , C07D413/12 , A61K31/4709 , A61P3/04
CPC分类号： C07D213/64 , C07C233/13 , C07C235/06 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C237/06 , C07C255/55 , C07C255/60 , C07C271/14 , C07C271/22 , C07C275/30 , C07C311/03 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D209/34 , C07D209/94 , C07D211/34 , C07D213/65 , C07D213/68 , C07D215/06 , C07D231/12 , C07D233/56 , C07D233/70 , C07D237/28 , C07D237/32 , C07D239/34 , C07D249/04 , C07D249/08 , C07D249/12 , C07D263/58 , C07D267/14 , C07D277/30 , C07D277/36 , C07D295/13 , C07D295/15 , C07D513/04
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

9. 发明授权

US07423067B2 Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists 失效
标题翻译：二苯基环戊基酰胺作为大麻素-1受体反向激动剂
公开(公告)号：US07423067B2
公开(公告)日：2008-09-09
申请号：US10507864
申请日：2003-03-21
申请人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Mark T. Goulet , James P. Jewell
发明人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Mark T. Goulet , James P. Jewell
IPC分类号： A61K31/165
CPC分类号： C07D207/38 , C07C233/59 , C07C235/40 , C07C235/82 , C07C237/24 , C07C255/60 , C07C271/24 , C07C317/44 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D205/04 , C07D207/16 , C07D207/48 , C07D211/60 , C07D211/62 , C07D213/56 , C07D213/61 , C07D213/82 , C07D213/89 , C07D265/30 , C07D307/24 , C07D307/68 , C07D309/08 , C07D401/04
摘要： Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
摘要翻译：结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管意外的精神药物，头部创伤，焦虑障碍，压力，癫痫，帕金森病，运动障碍和精神分裂症。这些化合物也可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。

10. 发明申请

US20080171692A1 Substituted amides 失效
公开(公告)号：US20080171692A1
公开(公告)日：2008-07-17
申请号：US12012463
申请日：2008-02-01
申请人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza
发明人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza
IPC分类号： A61K38/22 , A61K31/44 , A61K31/444 , A61K31/4439 , A61K31/365 , A61P3/04 , A61K31/485 , A61K31/357 , A61K31/155
CPC分类号： C07D213/64 , C07C233/13 , C07C235/06 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C237/06 , C07C255/55 , C07C255/60 , C07C271/14 , C07C271/22 , C07C275/30 , C07C311/03 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D209/34 , C07D209/94 , C07D211/34 , C07D213/65 , C07D213/68 , C07D215/06 , C07D231/12 , C07D233/56 , C07D233/70 , C07D237/28 , C07D237/32 , C07D239/34 , C07D249/04 , C07D249/08 , C07D249/12 , C07D263/58 , C07D267/14 , C07D277/30 , C07D277/36 , C07D295/13 , C07D295/15 , C07D513/04
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式